Nemaura Medical to Hold a Symposia at EASD in Barcelona on Thursday September 19, 2019
September 12 2019 - 9:15AM
Loughborough, England – September 12, 2019 –
Nemaura Medical, Inc. (NASDAQ: NMRD)
(“Nemaura”), a medical technology company focused on the
commercialization of SugarBEAT® as a non-invasive, affordable and
flexible Continuous Glucose Monitor (CGM) for use by diabetics and
pre-diabetics, today announced that Dr. Faz Chowdhury, Chief
Executive Officer, Dr. Fred Schaebsdau, VP Strategic Alliances, and
Dr Iain Cranson, a diabetes specialist based in the UK, will be
presenting at the 55th Annual Meeting of the European Association
for the Study of Diabetes (EASD) on Thursday, September 19, 2019 at
18:45 - 20:15 Central European Time at the Fira Barcelona Gran Via
(Maimonides Hall) in Barcelona, Spain. The evening symposia
will focus on the historic development of SugarBEAT®, its
application to all categories of diabetics and diabetes management,
clinical data and recent user experiences. The presentation
is titled: “SugarBEAT® Non-Invasive CGM User Study Results:
Diagnostic and Monitoring Applications Across Different Patient
Types and Clinical Settings.”
Dr. Faz Chowdhury, CEO of Nemaura commented, "We are very
pleased to be holding this symposia at this premier industry
conference. We will be reporting study results from our first
users, as well as sharing prior clinical data and user experiences.
We also plan to discuss our commercial launch plans, including
product availability in different territories. We look
forward to highlighting how SugarBEAT® differs from current
invasive CGM technologies and the potential to expand the
addressable market to include Type 2 diabetics and
pre-diabetics.”
The EASD Annual Meeting is Europe’s largest and most prominent
meeting on diabetes. The 55th Annual Meeting will be held September
16-20, 2019 at the Fira Barcelona Gran Via, Spain. The scientific
program offers researchers and healthcare professionals the
opportunity to share ideas and learn about cutting-edge research
and technology, groundbreaking studies and the significant advances
in diabetes research, treatment and care. Additional information is
available at: https://www.easd-industry.com
About Nemaura Medical, Inc.:
Nemaura Medical, Inc. (NASDAQ: NMRD), is a
medical technology company commercializing SugarBEAT® as a
non-invasive, affordable and flexible Continuous Glucose Monitor
(CGM) designed to help people with diabetes and pre-diabetics
better manage their glucose levels by spending more time in range.
Insulin users can adjunctively use SugarBEAT® when calibrated
by a finger stick reading. SugarBEAT® consists of a daily,
disposable adhesive skin-patch connected to a small form factor
rechargeable transmitter, connected via Bluetooth to a specially
designed mobile application, which displays glucose readings at
five-minute intervals throughout the day.
For more information visit:
www.NemauraMedical.com
www.SugarBEAT.com
Cautionary Statement Regarding Forward-Looking
Statements:
The statements in this press release that are
not historical facts, and may constitute forward-looking statements
that are based on current expectations and are subject to risks and
uncertainties that could cause actual future results to differ
materially from those expressed or implied by such statements.
Those risks and uncertainties include, but are not limited to,
risks related to regulatory approvals and the success of Nemaura’s
ongoing studies, including the safety and efficacy of Nemaura’s
SugarBEAT® system, the failure of future development and
preliminary marketing efforts, Nemaura’s ability to secure
additional commercial partnering arrangements, risks and
uncertainties relating to Nemaura and its partners’ ability to
develop, market and sell SugarBEAT®, the availability of
substantial additional equity or debt capital to support its
research, development and product commercialization activities, and
the success of its research, development, regulatory approval,
marketing and distribution plans and strategies, including those
plans and strategies related to SugarBEAT®. These and other risks
and uncertainties are identified and described in more detail in
Nemaura’s filings with the United States Securities and Exchange
Commission, including, without limitation, its Annual Report on
Form 10-K for the most recently completed fiscal year, its
Quarterly Reports on Form 10-Q, and its Current Reports on Form
8-K. Nemaura undertakes no obligation to publicly update or revise
any forward-looking statements.
Contact:
Crescendo Communications, LLC
212-671-1021
NMRD@crescendo-ir.com
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jul 2023 to Jul 2024